{
    "nct_id": "NCT03837899",
    "official_title": "Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies.",
    "inclusion_criteria": "* Max Age =17 years\n* Solid Tumors (except primary central nervous system malignant tumors): Patients must have a histopathologic confirmation of malignancy. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist\n* Non-Hodgkin's Lymphoma, limited to primary mediastinal B-cell lymphoma and anaplastic large cell lymphoma. Patients must have progressed or are refractory to standard therapies, and for whom no standard of care treatments exist.\n* Provision of diagnostic tumor sample mandated if available\n* Evaluable disease\n* No prior exposure to immune-mediated therapy\n* Adequate organ and marrow function\n* Life expectancy of at least 3 months\nHealthy volunteers allowed\nMust have minimum age of 0 Years\nMust have maximum age of 18 Years",
    "exclusion_criteria": "* History of allogeneic organ transplantation (exceptions may be allowed for NHL after discussion with Sponsor). History of autologous bone marrow transplant may be allowed (after discussion with Sponsor).\n* Active or prior documented autoimmune or inflammatory disorders (exceptions)\n* Uncontrolled intercurrent illness\n* History of primary immunodeficiency\n* Active infection including tuberculosis, hepatitis B, C or HIV\n* Any unresolved toxicity NCI CTCAE version 5.0 Grade â‰¥2 from previous anticancer therapy (exceptions)",
    "miscellaneous_criteria": ""
}